Coronavirus vaccine: Germany reports more AstraZeneca clot cases

Germany's medical regulator says it has received reports of 21 cases of rare blood clots in people who had recently received AstraZeneca's coronavirus vaccine.

AstraZeneca, pharma, coronavirus, vaccine
AP Berlin
1 min read Last Updated : Mar 29 2021 | 11:41 PM IST

Germany's medical regulator says it has received reports of 21 cases of rare blood clots in people who had recently received AstraZeneca's coronavirus vaccine.

The Paul Ehrlich Institute said in an email Monday to The Associated Press that seven people affected by the blood clots have died.

The incidence of an unusual form of blood clot in the head, known as sinus vein thrombosis, prompted several European countries to temporarily halt the use of the AstraZeneca vaccine earlier this month. After a review by medical experts. the European Union's medical regulator EMA recommended that warnings about possible rare side effects should be added to the vaccine information provided for patients and doctors.

Most EU countries have since resumed use of the vaccine.

The Paul Ehrlich Institute said that of the 21 cases reported in Germany until March 25, 12 also involved an abnormally low level of platelets in the patients' blood.

Of the 21 cases, 19 were in women ages 20 to 63, while two were in men ages 36 and 57.

During the period covered by the reports, some 2.27 million first doses of the AstraZeneca vaccine were administered in Germany.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirus VaccineAstraZenecaGermany

First Published: Mar 29 2021 | 11:40 PM IST

Next Story